Compare CSX Corporation (CSX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Twist Bioscience Corp — how do they compare? CSX Corporation trades at $47.4 (market cap $87.70B), while Twist Bioscience Corp trades at $161.72 (market cap $10.08B). The key difference: CSX Corporation is far larger — about 8.7× Twist Bioscience Corp's market cap, and CSX Corporation pays a 1.18% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Twist Bioscience Corp for 27 Days on average.
| CSX | TWST | |
|---|---|---|
Market Cap | $87.70B | $10.08B |
Volume | 6,980,781 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $53.21 | $205.00 |
52-Week Low | $33.68 | $25.45 |
Typical Hold Time | 55 Days | 27 Days |
Enterprise Value | $105.66B | $10.01B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.28, up 0.99% today, with a bullish technical signal and strong institutional interest. The railroad operator shows solid profitability with 22.2% net margins and 24.4% ROE, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analysts maintain a buy consensus with a $51 target, representing 8% upside. Recent news highlights upcoming Q3 earnings and institutional acquisitions.
CSX offers moderate upside potential with strong operational metrics offset by revenue pressures. Key opportunities include pricing power in freight rail and dividend growth, while risks involve economic sensitivity and competitive threats. The stock's premium valuation requires sustained execution to justify current levels.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
